PROVEN EFFICACY FOR CLINICAL ANTISEPSIS

Videne® Antiseptic Solution
Povidone-iodine 10% w/w cutaneous solution
Antiseptic Cleanser for Skin and Mucous Membranes

- Effective against a wide range of Gram positive and Gram negative bacteria (including MRSA), fungi and bacterial spores.
- Licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Irish Medicines Board (IMB) providing assurance of guaranteed safety and efficacy.
- A broad range of indications - skin, mucous membrane and wound antisepsis.
- High efficacy combined with excellent tolerability - no impairment of wound healing.

Premium anti-microbial skin, mucosal and wound disinfectant.

Licensed, povidone-iodine based formulation which is trusted by healthcare professionals and is supported by a large evidence base.\(^1\),\(^2\),\(^3\),\(^4\)
Videne® Antiseptic Solution

Range of Formats to Meet Clinical Requirements

Microorganisms on patient’s skin are understood to be the main cause of surgical site infections (SSIs) and blood stream infections (BSIs). With the Videne range of skin preparation solutions, the risk of infection can be reduced during surgical incision. This allows existing methods of skin preparation to be followed cost effectively without compromising patient safety.

Why Use Videne® Antiseptic Solution?

Broad Spectrum Efficacy and Trusted Protection

Povidone-iodine is extremely effective against a wide range of gram positive and gram negative bacteria (including MRSA), fungi and bacterial spores.

Cost Effective Solutions

For fast, effective and safe preparation of the incision site prior to surgery, with Videne Antiseptic Solution you have the added reassurance for this essential step in infection control.

Skin Delineation

Videne Antiseptic Solution offers appropriate and enhanced visualisation of the prepared area.

Licensed Povidone-Iodine Skin Disinfection

Videne Antiseptic Solution has been granted a marketing authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Irish Medicines Board (IMB), providing assurance that the product’s safety and efficacy has been assessed before marketing.

Summary of Product Characteristics

Videne Antiseptic Solution

Name of the Medicinal Product: Videne Antiseptic Solution 10% w/w cutaneous solution.

Active ingredient: iodine-Povidone 10% w/w. Indications: Disinfection of intact external skin as a mucus membrane antiseptic, for example prior to surgery, biopsy, punctures, dressing, dressing changes, catheterisation. Antiseptic wound treatment, burns, infected and superinfected dermatoes.

Unwanted Effects: Hypersensitivity reactions of the skin occur rarely. Anaphylactic reactions have been reported very rarely. Irritation of the skin after preparative disinfection have been reported in rare cases (“puddle formation”). An appreciable uptake of iodine can occur with long-term application to extensive skin areas. Very rarely iodine-induced hyperthyroidism can occur. Following absorption of larger amounts of povidone-iodine, thyrotoxicosis can occur due to the occurrence of additional electrolyte and serum sodium disturbances, renal insufficiency and severe metabolic acidosis has been described. Contraindications: Videne must not be used in patients with hyperthyroidism or other uncontrolled thyroid disease, in hereditary dermatitis (Chushin’s disease), before and after radiocautery application, in severe infections, in diabetic patients, in patients with a history of skin eruptions, in patients with a dense distribution of sebaceous glands or anosmia of any of the other ingredients. Videne should only be applied after careful diagnosis over a prolonged period and on extensive areas, in patients with multidual organic disease, after patients have been treated for thyroid diseases, and in those predisposed to hypothyroidism. In these cases early symptoms of hypothyroidism should be looked for up to 3 months after therapy has been discontinued and, where necessary, thyroid function monitored. Videne should be used only by an extremely limited extent in women and nurses suffering from the age of 6 months as the risk of hyperthyroidism cannot be completely ruled out. After applying Videne thyroid function should be checked. In the case of hypothyroidism, early treatment with thyroid hormones must be carried out. Accidental oral intake by the nursing infant must be avoided. Regular or prolonged use should be avoided with patients with thyroid disorders or those receiving lithium therapy. Warnings: Care must be taken when applying iodine to the oral cavity to avoid the risk of aspiration. The product must not be swallowed. Precautions: See SPC or label leaflet. Pregnancy and Lactation: Videne must only be administered following a very careful assessment and in an extremely limited amount during pregnancy and lactation. After applying iodine thyroid function must be monitored in the child. The accidental oral intake of Videne by the nursing infant must be expected (e.g. contact with treated site of the nursing mother’s body). If, due to the nature and extent of the application, a marked absorption of iodine is to be expected, it must be taken into account that the iodine content of the mother’s milk may increase.

Provision And Method of Administration: Used as a disinfectant or antiseptic for the skin or mucosa. Videne should be applied undiluted. For skin areas with a sparse distribution of sebaceous glands the exposure time is at least one minute, in skin areas with a dense distribution of sebaceous glands at least 10 minutes. The skin should be kept moist for the entire duration of the exposure time with undiluted Videne. For the antiseptic treatment of superficial wounds Videne is applied undiluted. In antiseptic topical therapy of burns wounds Videne is generally applied undiluted. For antiseptic irrigation washes and buttering Videne can be diluted. For application to the eye solutions buffered with phosphate buffer solutions are recommended. Videne should always be freshly prepared and used immediately. Sufficient Videne must be applied to wet the area to be treated completely. The antiseptic film that forms as it dries can be easily rinsed off with water. In repeated use, the frequency and duration of application depends on the indication for use. Wound treatment should be continued for as long as there are signs of an infection or a marked risk of infection of the wound. Should infection recur after discontinuing treatment with Videne, treatment can be resumed. The brown colouration caused by Videne is a property of the preparation and indicates its efficacy. Considerable decolourisation indicates exhaustion of the efficacy of the preparation.

Marketing Authorization Holder: Ecolab Ltd, Lortherton Way, Garforth, Leeds LS25 2JY, United Kingdom. License Number: 0K/PL/2000002502. RE: PN115/15.2. Sales Status: EU Wide read carefully the instructions on the SPC and on the label leaflet. Date Of Issue: Draft Of This: February 2011

For More Information Please Call: 0113 224 2480 (UK) or 01 276 3500 (IRELAND)